Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
- Study Title
- Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003)
- Teva Identifier
- NEUGR-003
- ClinicalTrials.gov Identifier
- NCT01126190
- Study Status
- Completed
- Trial Condition(s)
- Chemotherapy-induced Neutropenia
- Interventions
- Biological: Neugranin | Biological: Pegfilgrastim | Drug: Chemotherapy
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- 06/01/2010 - 02/01/2012
- Phase
- Phase 3
